DNER and prostate carcinoma: BET bromodomain inhibition is a promising therapeutic strategy for cancer, and there are several recently completed or ongoing BET bromodomain inhibitor clinical trials, including in prostate cancer (NCT02259114, NCT02711956, NCT02705469, NCT02391480).